DelveInsight launched a new report on Catheter-Related Bloodstream Infection Pipeline Insights 2020.
DelveInsight’s, “Catheter-related Bloodstream Infection -Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Catheter-related Bloodstream Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Catheter-related bloodstream infection (CRBSI) is defined as the presence of bacteremia originating from an intravascular (I.V.) catheters.
Key Company Involved:
1. Citius Pharmaceuticals
Mino-Lok provides anti-clotting properties to maintain patency in CVCs and also break down the biofilm barriers formed by bacterial colonies to eradicate the bacteria. This lock solution has been granted with Fast Track and Qualified Infectious Disease Product (QIDP) designation.
“The diagnosed incident cases of CRBSI, in 2020, were found to be 648,351 in the 7MM.”
Table of contents:
- Executive Summary
- Catheter-related Bloodstream Infection: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Catheter-related Bloodstream Infection – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Catheter-related Bloodstream Infection Collaboration Deals
- Late Stage Products (Phase III)
- Mino-Lok: Leonard-Meron Biosciences, Inc.
- Catheter-related Bloodstream Infection- Market Drivers and Barriers
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States